Daniel Geschwind
Neurology · Los Angeles, CANPI 1730102310
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,228 of the $7,419 with a category attached, or 97.4%. Biogen accounts for 97.4% of it on its own, with 1 other manufacturer making up the rest.
Across 6 payments — averaging $1236.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$7K
- Mitsubishi Tanabe Pharma Holdings America, Inc.$191
Across 8 payments — averaging $124,679 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tanabe Pharma America, Inc.$378K
- F. Hoffmann-la Roche AG$310K
- Mitsubishi Tanabe Pharma Holdings America, Inc.$309K
What the payments were for
- Consulting fees$7,22897%
- Food & beverage$1913%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 3 | $7,228 |
| Mitsubishi Tanabe Pharma Holdings America, Inc. | 3 | $191 |
How this compares
$7,419 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.